Sweden's Xspray posts narrow Q2 pretax loss as costs fall
Sweden's Xspray posts narrow Q2 pretax loss as costs fall
Overview
Sweden pharmaceutical developer reported no Q2 sales as products remain in clinical stage
Pretax loss for Q2 narrowed yr/yr, reflecting improved cost management
Company raised SEK 113 mln in oversubscribed rights issue to fund operations
Outlook
Xspray expects Dasynoc launch in US before end-2026, pending regulatory clearance
Company plans Nilopki FDA resubmission in Q4 2026; 2026 launch remains unlikely
Xspray maintains commercial readiness for Dasynoc and continues disciplined cost management
Result Drivers
NO COMMERCIAL SALES - Co reported no revenue as products remain in clinical and regulatory development
COST MANAGEMENT - Co said reduced operating expenses and improved operating result reflect cost-cutting measures
REGULATORY DELAYS - FDA requested additional information for Nilopki and approval for Dasynoc remains contingent on third-party manufacturing site clearance
Company press release: ID:nMFN1s58rB
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| SEK 0 |
|
Q2 Adjusted Loss Per Share |
| -SEK 0.87 |
|
Q2 Adjusted Free Cash Flow |
| -SEK 36.95 mln |
|
Q2 Pretax Loss |
| -SEK 39.79 mln |
|
Analyst Coverage
Wall Street's median 12-month price target for Xspray Pharma publ AB is SEK58.35, about 251.5% above its August 4 closing price of SEK16.60
Reuters Recommended Reads
Aug 4 - Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand
Aug 3 - Keros Therapeutics Q2 net loss narrows on lower expenses
Aug 5 - Novo CEO faces investor grilling after outlook hike soured by pipeline concerns
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)